AFG Earnings Preview: Street Cautious, Insider Sales Add Context

American Financial Group reports Q3 2026 results today with the stock sitting at $153, almost exactly at the analyst consensus price target of $154.50, leaving virtually no implied upside in the median estimate.

Options positioning has edged more defensive than usual into the print, though not dramatically so. The put/call ratio rose to 0.16 on November 3, above its 20-day average of 0.14 and the highest single-day reading in roughly six weeks. That is a mild uptick rather than a signal of acute anxiety. The borrow market confirms the lack of urgency among bears: share availability is effectively unconstrained, with lending pool capacity running at more than 9,000% of current short interest, and the cost to borrow at 0.33% remains negligible. Short interest itself is 2.2% of the free float, up roughly 6% over the past week but low in absolute terms. The stock gained 1.1% on the week, modestly behind a peer median of around 2.3% across names like CB, ACGL and EG.

The analyst debate centres on whether specialty pricing momentum can hold. The bull case rests on AFG's Q2 beat, where reported EPS of $2.82 cleared consensus of $2.37, premium growth of 6.2% and net investment income growth of 23.5% all came in ahead of expectations, and the specialty combined ratio of 91.5% benefited from 3.3 points of favourable reserve development. Alternative investment returns of 7.1% added further colour. The bear case points to softening renewal pricing across key lines: Specialty P&C renewal rates were flat at plus 5% versus plus 7% a year earlier, with Specialty Casualty and Specialty Financial both deteriorating further. Wells Fargo trimmed its target from $175 to $166 in October while maintaining its Overweight rating; Keefe, Bruyette and Woods cut from $153 to $147 at Market Perform. Both moves came in the weeks before the print and suggest the Street is marking down its near-term expectations even without changing its directional view.

The insider register adds a layer of caution. Co-CEO Carl Lindner III sold roughly $13 million of stock in late August, in two tranches at around $144, none of it under a 10b5-1 plan. The CFO also sold a smaller amount in September. Net insider activity over the past 90 days amounts to roughly minus $15.6 million in value. Neither the Lindner family's combined stake of around 13% nor the activist 13D filings both Carl and S. Craig Lindner lodged in April are themselves bearish signals; family-controlled companies sell stock for many reasons. But the timing, shortly after the Q2 beat and ahead of a print where the Street has been nudging targets lower, is worth noting.

Today's print is therefore a test of whether specialty underwriting margins held up as pricing decelerated, and whether alternative investment income can again do the heavy lifting it did in Q2.